Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Concert Pharmaceuticals, Inc. (CNCE)

4.5962   -0.164 (-3.44%) 12-06 09:53
Open: 4.72 Pre. Close: 4.76
High: 4.72 Low: 4.56
Volume: 41,786 Market Cap: 220(M)

Technical analysis

as of: 2022-12-06 9:17:39 AM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 6.5     One year: 7.39
Support: Support1: 4.32    Support2: 3.6
Resistance: Resistance1: 5.56    Resistance2: 6.32
Pivot: 4.89
Moving Average: MA(5): 4.82     MA(20): 4.81
MA(100): 5.9     MA(250): 4.55
MACD: MACD(12,26): -0.2     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 42.5     %D(3): 47
RSI: RSI(14): 40.7
52-week: High: 7.36  Low: 2.56
Average Vol(K): 3-Month: 440 (K)  10-Days: 229 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CNCE ] has closed above bottom band by 26.5%. Bollinger Bands are 57.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.11 - 5.15 5.15 - 5.18
Low: 4.64 - 4.67 4.67 - 4.7
Close: 4.71 - 4.77 4.77 - 4.81

Company Description

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Headline News

Mon, 05 Dec 2022
Civic Group Condemns Assault Of Three Journalists By Nigerian Policemen, Demands Sanctions For Erring Officers - SaharaReporters.com

Mon, 05 Dec 2022
Bullish insiders bet US$1.1m on Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Yahoo Eurosport UK

Tue, 29 Nov 2022
Concert Pharmaceuticals's Return On Capital Employed Insights - Concert Pharma (NASDAQ:CNCE) - Benzinga

Tue, 22 Nov 2022
Concert Pharmaceuticals Inc (CNCE) is up 1.81% in a Week, Should You Hold? - InvestorsObserver

Mon, 21 Nov 2022
Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research - Business Wire

Wed, 09 Nov 2022
Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference - Business Wire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 48 (M)
Shares Float 43 (M)
% Held by Insiders 3.9 (%)
% Held by Institutions 72.3 (%)
Shares Short 2,120 (K)
Shares Short P.Month 1,660 (K)

Stock Financials

EPS -2.72
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.77
Profit Margin (%) 0
Operating Margin (%) -288
Return on Assets (ttm) -38.6
Return on Equity (ttm) -108.7
Qtrly Rev. Growth -98.5
Gross Profit (p.s.) -1.15
Sales Per Share 0.66
EBITDA (p.s.) -1.9
Qtrly Earnings Growth 0
Operating Cash Flow -110 (M)
Levered Free Cash Flow -44 (M)

Stock Valuations

PE Ratio -1.76
PEG Ratio 0
Price to Book value 1.71
Price to Sales 7.12
Price to Cash Flow -2.09

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.